Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A particular
antihistamine drug used ineye drops to treatallergic conjunctivitis .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word epinastine.
Examples
-
Elestat, or epinastine solution, is used to treat itchiness caused by an eye allergy linked to exposure to tree pollen, grass and plants, animal dander, feathers, dust mites and molds.
unknown title 2011
-
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS ® (cyclosporine ophthalmic emulsion) 0.05% for dry eye and DIQUAS™ Ophthalmic Solution 3% (diquafosol tetrasodium) for dry eye.
unknown title 2011
-
Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis.
unknown title 2011
-
Total product co-promotion and royalty revenue, comprised of royalty revenue from net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% and co-promotion revenue from net sales of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05%, was $17.5 million for the fourth quarter of 2009, compared to
-
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% for dry eye.
-
Co-promotion revenue from ELESTAT will be dependent on the timing of a launch of a generic form of epinastine, which could occur in 2010.
-
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye.
-
Based upon historical timelines and our understanding of the FDA review cycle, we do not expect a generic epinastine product to launch in 2009.
-
Upon completing an evaluation of the situation Boehringer Ingelheim, the owner of the Elestat patent decided not to pursue or file suit against the companies currently seeking approval of a generic epinastine product.
-
Recently we have reported that several ANDA filings for a generic version of epinastine were filed with the FDA.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.